GLP-1 Agonists and Mental Health: Depression, Anxiety, Addiction

TL;DR

GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — were developed for diabetes and weight management, but emerging research points to effects on mood, anxiety, and addiction:

• Depression: a 2024 retrospective study of 1.6 million patients found lower rates of new depression diagnoses among those on semaglutide vs other diabetes drugs — and the effect persisted after controlling for weight loss.
• Addiction: GLP-1 receptors sit in the brain's reward circuit. Patients report reduced cravings for alcohol and nicotine; clinical trials for alcohol use disorder are underway.
• Mechanism: GLP-1 receptors are present in the hippocampus, amygdala, and prefrontal cortex. Animal studies show GLP-1 activation increases BDNF and reduces neuroinflammation — both mechanisms implicated in depression.
• Caveat: GLP-1 agonists are not approved for any psychiatric condition. Effects on mood are secondary, the data is still early, and a small number of patients report worsening mood early in treatment.

If you're on a GLP-1 medication and noticing mood changes — in either direction — tell your prescriber.

What are GLP-1 receptor agonists?

GLP-1 (glucagon-like peptide-1) is a hormone produced naturally in the gut after eating. It signals the pancreas to release insulin, slows gastric emptying, and reduces appetite. GLP-1 receptor agonists are synthetic versions of this hormone that last hours-to-days instead of minutes.

The major medications in clinical use:

Drug	Brand names	Indication	Mechanism
Semaglutide	Ozempic, Wegovy, Rybelsus	T2D, weight management	GLP-1 agonist
Tirzepatide	Mounjaro, Zepbound	T2D, weight management	Dual GLP-1 / GIP agonist
Liraglutide	Victoza, Saxenda	T2D, weight management	GLP-1 agonist
Dulaglutide	Trulicity	T2D	GLP-1 agonist
Exenatide	Byetta, Bydureon	T2D	GLP-1 agonist

What makes these drugs relevant to mental health is that GLP-1 receptors aren't limited to the gut and pancreas. They are present throughout the brain — including the hippocampus, amygdala, hypothalamus, and prefrontal cortex — regions directly involved in mood regulation, fear processing, memory, and reward.

What does the research show on GLP-1 and depression?

A growing body of evidence suggests a depression-protective effect, with the strongest signal from real-world data:

• A 2024 retrospective cohort study using electronic health records of 1.6 million patients with type 2 diabetes found semaglutide users had significantly lower rates of new depression diagnoses vs. matched patients on other diabetes drugs. The protective effect held after controlling for weight loss — suggesting it's not just "feeling better because you weigh less."
• The Mansur et al. 2023 study in Obesity showed semaglutide improved cognitive function and reduced depressive symptoms independent of weight-loss magnitude.
• Animal models consistently show GLP-1 receptor activation increases BDNF — the same neuroplasticity protein implicated in ketamine's antidepressant effect — and reduces neuroinflammation, a contributor to treatment-resistant depression.

The data is suggestive, not definitive — no randomized controlled trial has yet tested GLP-1 agonists specifically as antidepressants.

What about anxiety?

The anxiety picture is more mixed:

• Some patients report reduced anxiety, attributed to lower neuroinflammation, better metabolic stability, and gut-brain (vagal) signaling.
• A subset report increased anxiety, particularly in the first weeks of treatment.
• The FDA reviewed reports of suicidal ideation in GLP-1 users in 2023–2024; large-scale analyses have not established a causal link. The European Medicines Agency 2023 review concluded there was no evidence of increased suicide risk.

If you're starting a GLP-1 and feel anxiety getting worse, that's data worth bringing to your prescriber — not necessarily a reason to stop, but worth tracking carefully.

Why is there a connection to addiction and cravings?

This is the most striking emerging finding. Patients and clinicians have been reporting reduced cravings for alcohol, nicotine, and certain compulsive behaviors while on GLP-1 agonists. Three converging lines of evidence:

1. Mechanism plausibility — GLP-1 receptors are present in the mesolimbic dopamine pathway, the brain's reward circuit. The same circuit drives addiction.
2. Animal data — preclinical studies consistently show GLP-1 agonists reduce alcohol and drug self-administration in rodent models.
3. Real-world signal — a 2023 retrospective analysis showed lower rates of alcohol use disorder diagnoses among semaglutide users vs. matched controls.

Clinical trials specifically testing semaglutide for alcohol use disorder are underway, including Phase 2 studies registered on ClinicalTrials.gov. Results expected 2025–2027.

This is the area to watch over the next 24 months.

Is tirzepatide different?

Tirzepatide activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP receptors are also expressed in the brain. The dual mechanism may produce different neuropsychiatric effects than pure GLP-1 agonists — but mental health data specific to tirzepatide is still limited. Most published findings are on semaglutide and liraglutide.

If you're choosing between semaglutide and tirzepatide for primary metabolic reasons and mood is a secondary consideration, the existing evidence is stronger for semaglutide on the mental health side.

Why does this matter clinically?

For patients with comorbid obesity and depression — a very common overlap — GLP-1 agonists may offer dual benefit that traditional antidepressants don't. SSRIs frequently cause weight gain, which worsens metabolic health and can worsen depression in a feedback loop. A medication that addresses both directions at once could meaningfully change outcomes.

At Isha Health, patients often present with depression that's intertwined with metabolic health, chronic pain, and inflammation. While we specialize in ketamine-assisted therapy, understanding how GLP-1 agonists interact with mood and brain chemistry helps us coordinate care with prescribers when patients are on both — or considering them in combination.

Important caveat: GLP-1 agonists are not FDA-approved for the treatment of depression, anxiety, addiction, or any psychiatric condition. Any mood benefits are secondary effects. These medications should not be prescribed specifically for psychiatric use outside of clinical trials.

What should patients do?

• If you're on a GLP-1 and notice mood changes (in either direction), tell your prescriber. Track the change with a simple log — date, dose, what you noticed.
• If you're considering a GLP-1 primarily for weight or diabetes and you also have depression, mention it to your prescriber. The choice of agent may matter.
• If you have a history of suicidal ideation, that's worth flagging when starting any new medication, GLP-1 or otherwise.
• If you experience worsening depression, anxiety, or suicidal thoughts on any medication, get medical attention. Call 988 (U.S. Suicide & Crisis Lifeline) or go to the nearest emergency department.

FAQs

Do GLP-1 agonists help with depression?

Emerging evidence suggests they may, with the strongest signal from a 2024 retrospective study of 1.6 million patients showing lower rates of new depression diagnoses among semaglutide users. They are not FDA-approved for depression treatment — randomized antidepressant trials haven't yet been run.

Can GLP-1 agonists make depression worse?

A subset of patients report worsening mood, particularly in the first weeks. Large-scale analyses have not established a causal link with suicidal ideation, but individual responses vary. Track mood changes and discuss with your prescriber.

Do GLP-1 agonists help with alcohol cravings?

Patient reports and animal studies suggest yes. GLP-1 receptors sit in the brain's reward pathway, and rodent studies consistently show reduced alcohol consumption with GLP-1 agonists. Phase 2 trials in humans are underway; data expected 2025–2027.

Can I take a GLP-1 agonist alongside ketamine therapy?

There's no established contraindication, and the two work through different mechanisms (GLP-1 receptors vs. NMDA glutamate receptors). Coordinate with both prescribers and make sure your ketamine provider knows about your GLP-1 medication when evaluating your protocol.

Are GLP-1 agonists better than SSRIs for depression?

There's no head-to-head trial. SSRIs are FDA-approved antidepressants with decades of data; GLP-1 agonists are off-label-mood-effects-only and the depression data is still early-stage. For someone with comorbid obesity and depression, GLP-1 may be more appealing because SSRIs often cause weight gain — but that's a metabolic argument, not an antidepressant-efficacy one.

Is the mood benefit just from losing weight?

The Mansur 2023 study and the 2024 cohort study both suggest the effect persists after controlling for weight loss — implying a direct neurobiological mechanism in addition to any weight-mediated benefit. That said, weight loss itself improves mood in many patients with obesity, so disentangling the two completely is hard.

---

Related Articles

• Ashwagandha for Mental Health: Benefits and How to Use It
• Ketamine and Neuroinflammation: Anti-Inflammatory Mechanisms
• Ketamine and Alcohol Use Disorder: Craving Reduction

---

Considering ketamine therapy? Isha Health offers physician-led at-home treatment via telemedicine in California, Texas, Florida, Colorado, Georgia, Oregon, and Washington. With an 88.8% improvement rate. Check appointment availability.